ALS Riddle Unravels: Microglia's Dual Role in Neuron Death and Survival

A foundational 2016 Nature study revealed that specialized brain immune cells, known as microglia, can actively destroy crucial motor neurons in a mouse model of Amyotrophic Lateral Sclerosis (ALS) by using specific cellular antennae called TAM receptors. This groundbreaking discovery shifted our understanding, showing that microglia are not just passive cleanup crew, but can turn into active destroyers of neurons, a role that is still being intensely studied in 2026. However, recent research in 2025 and 2026 paints a more complex picture, suggesting these very cells also have protective roles, making their overall contribution to ALS progression a critical and evolving area of focus for scientists. ALS, often called Lou Gehrig's disease, is a devastating illness that progressively weakens muscles, eventually leading to paralysis and death due to the loss of motor neurons. Current treatments offer limited benefits, highlighting an urgent need for new approaches. The recognition of microglia complex behavior, including the emergence of 'disease-associated microglia' (DAM) forms, is now guiding a new wave of therapeutic strategies that move beyond broad anti-inflammatory drugs to more targeted interventions. Researchers are exploring ways to 'recalibrate' microglial functions, either by blocking harmful activities like those mediated by TAM receptors or by enhancing their beneficial roles, such as clearing toxic protein clumps like TDP-43 and SOD1. Combination therapies that target multiple cell types, including microglia and astrocytes, are also showing promise in preclinical studies. Looking ahead, the focus is squarely on translating these detailed mechanistic insights from mouse model into effective human treatments. Scientists are actively investigating compounds that can specifically control microglial states, and several investigational drugs are in clinical trials for ALS, aiming to modulate neuroinflammation and other disease pathways. The ultimate goal is to develop therapies that can slow or even halt the relentless progression of ALS, building on a deeper understanding of how the brain's own immune cells contribute to, and potentially fight against, this deadly disease.